---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-145434"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:19:20.442526+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial

## Summary
- Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.
- No patient had received TNG348 in combination with olaparib; single-agent toxicity drove decision.
- Cash runway extended into 2027; PRMT5 (TNG908/TNG462) and CoREST programs remain on track with clinical update expected H2 2024.
- CEO Barbara Weber cited patient safety as priority; stock may react to loss of pipeline candidate.

## SEC filing metadata
- accession: 0001193125-24-145434
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312524145434/0001193125-24-145434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312524145434/d823505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-145434
- JSON: https://secwatch.observer/filing/0001193125-24-145434.json
- Plain text: https://secwatch.observer/filing/0001193125-24-145434.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.